222 related articles for article (PubMed ID: 38015374)
1. Genomic Landscape of Pleural Mesothelioma and Therapeutic Aftermaths.
Nash A; Creaney J
Curr Oncol Rep; 2023 Dec; 25(12):1515-1522. PubMed ID: 38015374
[TBL] [Abstract][Full Text] [Related]
2. BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma.
McGregor SM; McElherne J; Minor A; Keller-Ramey J; Dunning R; Husain AN; Vigneswaran W; Fitzpatrick C; Krausz T
Hum Pathol; 2017 Feb; 60():86-94. PubMed ID: 27771374
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of
Kukuyan AM; Sementino E; Kadariya Y; Menges CW; Cheung M; Tan Y; Cai KQ; Slifker MJ; Peri S; Klein-Szanto AJ; Rauscher FJ; Testa JR
Cancer Res; 2019 Aug; 79(16):4113-4123. PubMed ID: 31151962
[TBL] [Abstract][Full Text] [Related]
4. Heterogeneous Contributing Factors in MPM Disease Development and Progression: Biological Advances and Clinical Implications.
Tolani B; Acevedo LA; Hoang NT; He B
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29342862
[TBL] [Abstract][Full Text] [Related]
5. Genomic landscape of pleural and peritoneal mesothelioma tumours.
Hiltbrunner S; Fleischmann Z; Sokol ES; Zoche M; Felley-Bosco E; Curioni-Fontecedro A
Br J Cancer; 2022 Nov; 127(11):1997-2005. PubMed ID: 36138075
[TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations.
Zauderer MG; Bott M; McMillan R; Sima CS; Rusch V; Krug LM; Ladanyi M
J Thorac Oncol; 2013 Nov; 8(11):1430-3. PubMed ID: 24128712
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive genomic and tumour immune profiling reveals potential therapeutic targets in malignant pleural mesothelioma.
Creaney J; Patch AM; Addala V; Sneddon SA; Nones K; Dick IM; Lee YCG; Newell F; Rouse EJ; Naeini MM; Kondrashova O; Lakis V; Nakas A; Waller D; Sharkey A; Mukhopadhyay P; Kazakoff SH; Koufariotis LT; Davidson AL; Ramarao-Milne P; Holmes O; Xu Q; Leonard C; Wood S; Grimmond SM; Bueno R; Fennell DA; Pearson JV; Robinson BW; Waddell N
Genome Med; 2022 May; 14(1):58. PubMed ID: 35637530
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitors in malignant pleural mesothelioma: promises and challenges.
Ceresoli GL; Bonomi M; Sauta MG
Expert Rev Anticancer Ther; 2016 Jul; 16(7):673-5. PubMed ID: 27224058
[No Abstract] [Full Text] [Related]
9. Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study.
Lo Iacono M; Monica V; Righi L; Grosso F; Libener R; Vatrano S; Bironzo P; Novello S; Musmeci L; Volante M; Papotti M; Scagliotti GV
J Thorac Oncol; 2015 Mar; 10(3):492-9. PubMed ID: 25514803
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of NF2 hemizygous loss detected by fluorescence in situ hybridization in diagnosing pleural mesothelioma in tissue and cytology material: A multi-institutional study.
Sa-Ngiamwibool P; Hamasaki M; Kinoshita Y; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Kasai T; Kushitani K; Takeshima Y; Hiroshima K; Iwasaki A; Nabeshima K
Lung Cancer; 2023 Jan; 175():27-35. PubMed ID: 36442384
[TBL] [Abstract][Full Text] [Related]
11. Malignant cells from pleural fluids in malignant mesothelioma patients reveal novel mutations.
Sneddon S; Dick I; Lee YCG; Musk AWB; Patch AM; Pearson JV; Waddell N; Allcock RJN; Holt RA; Robinson BWS; Creaney J
Lung Cancer; 2018 May; 119():64-70. PubMed ID: 29656754
[TBL] [Abstract][Full Text] [Related]
12. Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.
Patil NS; Righi L; Koeppen H; Zou W; Izzo S; Grosso F; Libener R; Loiacono M; Monica V; Buttigliero C; Novello S; Hegde PS; Papotti M; Kowanetz M; Scagliotti GV
J Thorac Oncol; 2018 Jan; 13(1):124-133. PubMed ID: 29079455
[TBL] [Abstract][Full Text] [Related]
13. BAP1 gene mutations in Egyptian patients with advanced sporadic malignant pleural mesothelioma (MPM): relation with clinical outcomes and survival.
Bahnasy AA; El-Din RS; Sabri NA; Abdel-Rahman CA; Bastawisy AE
Cancer Genet; 2018 Dec; 228-229():83-92. PubMed ID: 30553477
[TBL] [Abstract][Full Text] [Related]
14. Integrative Molecular Characterization of Malignant Pleural Mesothelioma.
Hmeljak J; Sanchez-Vega F; Hoadley KA; Shih J; Stewart C; Heiman D; Tarpey P; Danilova L; Drill E; Gibb EA; Bowlby R; Kanchi R; Osmanbeyoglu HU; Sekido Y; Takeshita J; Newton Y; Graim K; Gupta M; Gay CM; Diao L; Gibbs DL; Thorsson V; Iype L; Kantheti H; Severson DT; Ravegnini G; Desmeules P; Jungbluth AA; Travis WD; Dacic S; Chirieac LR; Galateau-Sallé F; Fujimoto J; Husain AN; Silveira HC; Rusch VW; Rintoul RC; Pass H; Kindler H; Zauderer MG; Kwiatkowski DJ; Bueno R; Tsao AS; Creaney J; Lichtenberg T; Leraas K; Bowen J; ; Felau I; Zenklusen JC; Akbani R; Cherniack AD; Byers LA; Noble MS; Fletcher JA; Robertson AG; Shen R; Aburatani H; Robinson BW; Campbell P; Ladanyi M
Cancer Discov; 2018 Dec; 8(12):1548-1565. PubMed ID: 30322867
[TBL] [Abstract][Full Text] [Related]
15. The Rocky Road from Preclinical Findings to Successful Targeted Therapy in Pleural Mesothelioma.
Paajanen J; Bueno R; De Rienzo A
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362209
[TBL] [Abstract][Full Text] [Related]
16. Is the patient with mesothelioma without hope?
Maat AP; Cornelissen R; Bogers AJ; Takkenberg JJ
Future Oncol; 2015; 11(24 Suppl):11-4. PubMed ID: 26638916
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic and genetic characteristics of young patients with pleural diffuse malignant mesothelioma.
Vivero M; Bueno R; Chirieac LR
Mod Pathol; 2018 Jan; 31(1):122-131. PubMed ID: 28884745
[TBL] [Abstract][Full Text] [Related]
18. BAP1 protein is a progression factor in malignant pleural mesothelioma.
Arzt L; Quehenberger F; Halbwedl I; Mairinger T; Popper HH
Pathol Oncol Res; 2014 Jan; 20(1):145-51. PubMed ID: 23963927
[TBL] [Abstract][Full Text] [Related]
19. Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma.
Kalra N; Zhang J; Thomas A; Xi L; Cheung M; Talarchek J; Burkett S; Tsokos MG; Chen Y; Raffeld M; Miettinen M; Pastan I; Testa JR; Hassan R
BMC Cancer; 2015 May; 15():376. PubMed ID: 25952750
[TBL] [Abstract][Full Text] [Related]
20. BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma.
Alakus H; Yost SE; Woo B; French R; Lin GY; Jepsen K; Frazer KA; Lowy AM; Harismendy O
J Transl Med; 2015 Apr; 13():122. PubMed ID: 25889843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
